ALEMBIC PHARMACEUTICALS LTD. - 533573 - Clarification sought from Alembic Pharmaceuticals Ltd
The Exchange has sought clarification from Alembic Pharmaceuticals Ltd on April 16th , 2020 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Shareholding for the Period Ended March 31, 2020
Alembic Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
With reference to the captioned matter, please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2020, received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of our Company. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Certificate Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2020
With reference to the captioned subject, we enclose herewith Certificate under Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 31st March, 2020, issued by M/s. Samdani Shah & Kabra, Practising Company Secretaries, Vadodara. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Charandeep Singh SalujaDesignation :- Company Secretary and Compliance Officer ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith our press release titled 'Alembic Group commits Rs. 10 crore towards the COVID 19 Pandemic'. We request you to kindly take the same on record. Alembic says enough capacity to meet rising demand for azithromycin
Drug maker Alembic Pharmaceuticals Ltd has informed that the company has enough capacity to meet the demand arising from the emergency situation foll ALEMBIC PHARMACEUTICALS LTD. - 533573 - Closure of Trading Window
With reference to the captioned matter, this is to inform the exchange that in terms of the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives framed pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company will remain closed from 1st April, 2020 till 48 hours after the declaration of the audited financial results for the quarter and financial year ended 31st March, 2020. The date of the Board Meeting for inter alia considering the audited financial results for the quarter and financial year ended 31st March, 2020, will be intimated in due course. We request you to kindly take the same on record.
On analyst call, Alembic Pharma says China supply chain returning to normal
Alembic Pharma held a conference call with analysts to discuss the impact of the coronavirus pandemic. Listen to the entire call transcript here. Key takeaways: - Seeing China supply chains normalize, as coronavirus cases fall in the country - Currently not seeing impact on business across markets, in wait and watch mode but pharma industry is so far seeing relatively less negative effects - Closely watching trials of coronavirus treatments for positive outcomes, particularly the chloroquine+azithromycin combination treatments ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The exchange is hereby informed that the Company will hold Investor's Conference Call on 20th March, 2020 to discuss the impact of COVID-19 on the Company as per the enclosed details. We request you to kindly take the same on record.